Yes, long-term use of Revlimid (lenalidomide) and Velcade (bortezomib) is common in the treatment of myeloma. These medications are often part of continuous therapy or maintenance treatment strategies, which are aimed at increasing progression-free survival and overall survival rates. Continuous therapy with these drugs ... read more

Yes, long-term use of Revlimid (lenalidomide) and Velcade (bortezomib) is common in the treatment of myeloma. These medications are often part of continuous therapy or maintenance treatment strategies, which are aimed at increasing progression-free survival and overall survival rates. Continuous therapy with these drugs continues until disease progression, and maintenance treatment may vary in duration based on individual cases. This approach has become more prevalent as it has been shown to improve survival rates in myeloma patients.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

8 Facts About Myeloma Treatments | MyMyelomaTeam

Revlimid (Lenalidomide) for Myeloma | MyMyelomaTeam